Literature DB >> 32495967

Reader Response: Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases.

Carolin Schwake1, Kerstin Hellwig1, Ralf Gold1, Ilya Ayzenberg1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32495967     DOI： 10.1002/ana.25805

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  3 in total

Review 1.  [Treatment of antibody-mediated encephalomyelitis : Strategies for the treatment of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease].

Authors:  Ilya Ayzenberg; Ingo Kleiter
Journal:  Nervenarzt       Date:  2021-03-30       Impact factor: 1.214

2.  Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.

Authors:  Marius Ringelstein; Ilya Ayzenberg; Gero Lindenblatt; Katinka Fischer; Anna Gahlen; Giovanni Novi; Helen Hayward-Könnecke; Sven Schippling; Paulus S Rommer; Barbara Kornek; Tobias Zrzavy; Damien Biotti; Jonathan Ciron; Bertrand Audoin; Achim Berthele; Katrin Giglhuber; Helene Zephir; Tania Kümpfel; Robert Berger; Joachim Röther; Vivien Häußler; Jan-Patrick Stellmann; Daniel Whittam; Anu Jacob; Markus Kraemer; Antoine Gueguen; Romain Deschamps; Antonios Bayas; Martin W Hümmert; Corinna Trebst; Axel Haarmann; Sven Jarius; Brigitte Wildemann; Matthias Grothe; Nadja Siebert; Klemens Ruprecht; Friedemann Paul; Nicolas Collongues; Romain Marignier; Michael Levy; Michael Karenfort; Michael Deppe; Philipp Albrecht; Kerstin Hellwig; Ralf Gold; Hans-Peter Hartung; Sven G Meuth; Ingo Kleiter; Orhan Aktas
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-11-16

3.  MOG antibody-associated encephalomyelitis mimicking bacterial meningomyelitis following ChAdOx1 nCoV-19 vaccination: a case report.

Authors:  Jordi Kühne Escolà; Cornelius Deuschl; Andreas Junker; Fabian Dusse; Refik Pul; Christoph Kleinschnitz; Martin Köhrmann; Benedikt Frank
Journal:  Ther Adv Neurol Disord       Date:  2022-01-19       Impact factor: 6.570
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.